Table 1 Patient, tumour and treatment characteristics

Number of patients

1,540

128

1,412

Number of IBTRs

98

12

86

Number of deaths (from or with disease)

117

12

105

Characteristic

Number (%)

Number (%)

Number (%)

Menopausal status

   Pre- or perimenopausal

544 (35.3)

127 (99.2)

417 (29.5)

   Postmenopausal

996 (64.7)

1 (0.8)

995 (70.5)

Size of tumour

   Less than 1.0 cm

319 (20.7)

15 (11.7)

304 (21.5)

   1 to 2 cm

689 (44.7)

43 (33.6)

646 (45.8)

   2 to 5 cm

516 (33.5)

64 (50.0)

452 (32.0)

   Greater than 5 cm

16 (1.0)

6 (4.7)

10 (0.7)

Oestrogen receptor

   Negative

242 (15.7)

46 (35.9)

196 (13.9)

   Equivocal

67 (4.4)

14 (10.9)

53 (3.8)

   Positive

858 (55.7)

57 (44.5)

801 (56.7)

   Unknown/not done

373 (24.2)

11 (8.6)

362 (25.6)

Progesterone receptor

   Negative

335 (21.8)

47 (36.7)

288 (20.4)

   Equivocal

104 (6.8)

15 (11.7)

89 (6.3)

   Positive

727 (47.2)

55 (43.0)

672 (47.6)

   Unknown/not done

374 (24.3)

11 (8.6)

363 (25.7)

Histological grade

   Grade 1

306 (19.9)

12 (9.4)

294 (20.8)

   Grade '2'

563 (36.6)

38 (29.7)

525 (37.2)

   Grade 3

428 (27.8)

62 (48.4)

366 (25.9)

   Unknown/not done

243 (15.8)

16 (12.5)

227 (16.1)

Lymphatic invasion (1 unknown)

   Yes

202 (13.1)

19 (14.8)

183 (13.0)

   No

1,337 (86.8)

109 (85.2)

1,228 (87.0)

Vascular invasion (2 unknown)

   Yes

55 (3.6)

6 (4.7)

49 (3.5)

   No

1,483 (96.3)

122 (95.3)

1,361 (96.4)

Intraductal component (2 unknown)

   Present

957 (62.2)

69 (53.9)

888 (62.9)

   Absent

581 (37.7)

59 (46.1)

522 (37.0)

Multicentricity

   Yes

95 (6.2)

8 (6.3)

87 (6.2)

   No

1,437 (93.3)

119 (93.0)

1,318 (93.3)

   Unknown/not done

8 (0.5)

1 (0.8)

7 (0.5)

Radiation therapy

1,300 (84.4)

118 (92.2)

1,182 (83.7)

Adjuvant treatment

   Hormone therapy

758 (49.2)

23 (18.0)

735 (52.1)

   Chemotherapy

239 (15.5)

55 (43.0)

184 (13.0)

   Hormone and chemotherapy

55 (3.6)

5 (0.3)

50 (3.2)